A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma

Follicular lymphoma (FL) is the second most frequent subtype of B non-Hodgkin's lymphomas (NHL) for which the treatment is based on the use of anti-CD20 mAbs. NK cells play a crucial role in their mechanism of action and the number of these cells mediating antibody-dependent cell cycotoxicity (...

Full description

Bibliographic Details
Main Authors: Emilie Decaup, Cédric Rossi, Pauline Gravelle, Camille Laurent, Julie Bordenave, Marie Tosolini, Anne Tourette, Emeline Perrial, Charles Dumontet, Mary Poupot, Christian Klein, Ariel Savina, Jean-Jacques Fournié, Christine Bezombes
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01943/full
id doaj-edac4580725a42f69c8ffc364c78d22b
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Emilie Decaup
Emilie Decaup
Emilie Decaup
Cédric Rossi
Cédric Rossi
Cédric Rossi
Cédric Rossi
Pauline Gravelle
Pauline Gravelle
Pauline Gravelle
Pauline Gravelle
Camille Laurent
Camille Laurent
Camille Laurent
Camille Laurent
Julie Bordenave
Julie Bordenave
Julie Bordenave
Marie Tosolini
Anne Tourette
Emeline Perrial
Charles Dumontet
Mary Poupot
Mary Poupot
Mary Poupot
Christian Klein
Ariel Savina
Jean-Jacques Fournié
Jean-Jacques Fournié
Jean-Jacques Fournié
Christine Bezombes
Christine Bezombes
Christine Bezombes
spellingShingle Emilie Decaup
Emilie Decaup
Emilie Decaup
Cédric Rossi
Cédric Rossi
Cédric Rossi
Cédric Rossi
Pauline Gravelle
Pauline Gravelle
Pauline Gravelle
Pauline Gravelle
Camille Laurent
Camille Laurent
Camille Laurent
Camille Laurent
Julie Bordenave
Julie Bordenave
Julie Bordenave
Marie Tosolini
Anne Tourette
Emeline Perrial
Charles Dumontet
Mary Poupot
Mary Poupot
Mary Poupot
Christian Klein
Ariel Savina
Jean-Jacques Fournié
Jean-Jacques Fournié
Jean-Jacques Fournié
Christine Bezombes
Christine Bezombes
Christine Bezombes
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
Frontiers in Immunology
ADCC—antibody dependent cellular cytotoxicity
NK cells
modelization
3D co-culture model
follicular lymphoma
author_facet Emilie Decaup
Emilie Decaup
Emilie Decaup
Cédric Rossi
Cédric Rossi
Cédric Rossi
Cédric Rossi
Pauline Gravelle
Pauline Gravelle
Pauline Gravelle
Pauline Gravelle
Camille Laurent
Camille Laurent
Camille Laurent
Camille Laurent
Julie Bordenave
Julie Bordenave
Julie Bordenave
Marie Tosolini
Anne Tourette
Emeline Perrial
Charles Dumontet
Mary Poupot
Mary Poupot
Mary Poupot
Christian Klein
Ariel Savina
Jean-Jacques Fournié
Jean-Jacques Fournié
Jean-Jacques Fournié
Christine Bezombes
Christine Bezombes
Christine Bezombes
author_sort Emilie Decaup
title A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
title_short A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
title_full A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
title_fullStr A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
title_full_unstemmed A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
title_sort tridimensional model for nk cell-mediated adcc of follicular lymphoma
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2019-08-01
description Follicular lymphoma (FL) is the second most frequent subtype of B non-Hodgkin's lymphomas (NHL) for which the treatment is based on the use of anti-CD20 mAbs. NK cells play a crucial role in their mechanism of action and the number of these cells mediating antibody-dependent cell cycotoxicity (ADCC) in the peripheral blood of FL patients predict the outcome. However, their presence in FL biopsies, their activation and their role have been poorly investigated. Moreover, in vitro studies have not deciphered the exact signaling cascades triggered by NK cells in presence of anti-CD20 mAbs on both effector and target cells in a relevant FL model. We performed in silico analyses and ex vivo functional assays to determine the presence and the activation status of NK cells in FL biopsies. We modelized ADCC phenomenon by developing a co-culture model composed by 3D-cultured FL cells and NK cells. Thus, we investigated the biological effect of anti-CD20 mAbs by fluorescent microscopy and the phosphorylation status of survival pathways by cell bar coding phosphoflow in target cells. In parallel, we measured the status of activation of downstream FcγRIIIa signaling pathways in effector cells and their activation (CD69, perforin, granzyme B, IFNγ) by flow cytometry. We determined by in vivo experiments the effects of anti-CD20 mAbs in presence of NK cells in SCID-Beige engrafted FL mice. Here, we show that functional NK cells infiltrate FL biopsies, and that their presence tends to correlate with the survival of FL patients. Using our 3D co-culture model, we show that rituximab and GA101 are able to promote degranulation, CD69 expression, IFNγ production and activate FcγRIIIa signaling cascade in NK cells, and inhibit survival pathways and induce apoptosis in FL cells. The effect of GA101 seems to be more pronounced as observed in vivo in a xenograft FL model. This study strongly supports the role of NK cells in FL and highlights the application of the 3D co-culture model for in vitro validation.
topic ADCC—antibody dependent cellular cytotoxicity
NK cells
modelization
3D co-culture model
follicular lymphoma
url https://www.frontiersin.org/article/10.3389/fimmu.2019.01943/full
work_keys_str_mv AT emiliedecaup atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT emiliedecaup atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT emiliedecaup atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT cedricrossi atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT cedricrossi atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT cedricrossi atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT cedricrossi atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT paulinegravelle atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT paulinegravelle atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT paulinegravelle atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT paulinegravelle atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT camillelaurent atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT camillelaurent atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT camillelaurent atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT camillelaurent atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT juliebordenave atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT juliebordenave atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT juliebordenave atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT marietosolini atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT annetourette atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT emelineperrial atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT charlesdumontet atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT marypoupot atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT marypoupot atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT marypoupot atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT christianklein atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT arielsavina atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT jeanjacquesfournie atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT jeanjacquesfournie atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT jeanjacquesfournie atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT christinebezombes atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT christinebezombes atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT christinebezombes atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT emiliedecaup tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT emiliedecaup tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT emiliedecaup tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT cedricrossi tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT cedricrossi tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT cedricrossi tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT cedricrossi tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT paulinegravelle tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT paulinegravelle tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT paulinegravelle tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT paulinegravelle tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT camillelaurent tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT camillelaurent tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT camillelaurent tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT camillelaurent tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT juliebordenave tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT juliebordenave tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT juliebordenave tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT marietosolini tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT annetourette tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT emelineperrial tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT charlesdumontet tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT marypoupot tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT marypoupot tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT marypoupot tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT christianklein tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT arielsavina tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT jeanjacquesfournie tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT jeanjacquesfournie tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT jeanjacquesfournie tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT christinebezombes tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT christinebezombes tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
AT christinebezombes tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma
_version_ 1716750379170922496
spelling doaj-edac4580725a42f69c8ffc364c78d22b2020-11-24T21:12:38ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-08-011010.3389/fimmu.2019.01943461510A Tridimensional Model for NK Cell-Mediated ADCC of Follicular LymphomaEmilie Decaup0Emilie Decaup1Emilie Decaup2Cédric Rossi3Cédric Rossi4Cédric Rossi5Cédric Rossi6Pauline Gravelle7Pauline Gravelle8Pauline Gravelle9Pauline Gravelle10Camille Laurent11Camille Laurent12Camille Laurent13Camille Laurent14Julie Bordenave15Julie Bordenave16Julie Bordenave17Marie Tosolini18Anne Tourette19Emeline Perrial20Charles Dumontet21Mary Poupot22Mary Poupot23Mary Poupot24Christian Klein25Ariel Savina26Jean-Jacques Fournié27Jean-Jacques Fournié28Jean-Jacques Fournié29Christine Bezombes30Christine Bezombes31Christine Bezombes32Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceCHU Dijon, Hématologie Clinique, Hôpital François Mitterand, Dijon, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceDepartment of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceDepartment of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FrancePôle Technologique du Centre de Recherches en Cancérologie de Toulouse, Toulouse, FranceINSERM1052/CNRS5286/Université Claude Bernard, Lyon, FranceINSERM1052/CNRS5286/Université Claude Bernard, Lyon, FranceINSERM1052/CNRS5286/Université Claude Bernard, Lyon, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceRoche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, SwitzerlandInstitut Roche, Boulogne-Billancourt, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceFollicular lymphoma (FL) is the second most frequent subtype of B non-Hodgkin's lymphomas (NHL) for which the treatment is based on the use of anti-CD20 mAbs. NK cells play a crucial role in their mechanism of action and the number of these cells mediating antibody-dependent cell cycotoxicity (ADCC) in the peripheral blood of FL patients predict the outcome. However, their presence in FL biopsies, their activation and their role have been poorly investigated. Moreover, in vitro studies have not deciphered the exact signaling cascades triggered by NK cells in presence of anti-CD20 mAbs on both effector and target cells in a relevant FL model. We performed in silico analyses and ex vivo functional assays to determine the presence and the activation status of NK cells in FL biopsies. We modelized ADCC phenomenon by developing a co-culture model composed by 3D-cultured FL cells and NK cells. Thus, we investigated the biological effect of anti-CD20 mAbs by fluorescent microscopy and the phosphorylation status of survival pathways by cell bar coding phosphoflow in target cells. In parallel, we measured the status of activation of downstream FcγRIIIa signaling pathways in effector cells and their activation (CD69, perforin, granzyme B, IFNγ) by flow cytometry. We determined by in vivo experiments the effects of anti-CD20 mAbs in presence of NK cells in SCID-Beige engrafted FL mice. Here, we show that functional NK cells infiltrate FL biopsies, and that their presence tends to correlate with the survival of FL patients. Using our 3D co-culture model, we show that rituximab and GA101 are able to promote degranulation, CD69 expression, IFNγ production and activate FcγRIIIa signaling cascade in NK cells, and inhibit survival pathways and induce apoptosis in FL cells. The effect of GA101 seems to be more pronounced as observed in vivo in a xenograft FL model. This study strongly supports the role of NK cells in FL and highlights the application of the 3D co-culture model for in vitro validation.https://www.frontiersin.org/article/10.3389/fimmu.2019.01943/fullADCC—antibody dependent cellular cytotoxicityNK cellsmodelization3D co-culture modelfollicular lymphoma